Dual Action Diabetes Therapy Revolutionary Combination Peptide for Weight and Blood Sugar

Type 2 diabetes and obesity have reached epidemic proportions globally. Eli Lilly presents a novel therapeutic combining the effects of two important regulatory peptides – GIP and GLP-1 – into a single, more powerful treatment that addresses blood sugar control and weight management simultaneously.

The Problem

Type 2 diabetes and obesity are intertwined epidemics affecting hundreds of millions of people worldwide. High blood sugar and excess body weight are key risk factors for cardiovascular disease, kidney disease, and numerous other complications. While treatments exist for diabetes and obesity separately, the dual therapeutic challenge of simultaneously controlling blood sugar and reducing weight remains difficult. GLP-1 receptor agonists have revolutionized diabetes and obesity treatment by mimicking the effects of glucagon-like peptide-1, a natural hormone that regulates blood sugar and appetite. GLP-1 based therapies have demonstrated remarkable efficacy, with some patients achieving 10-15% weight loss alongside excellent blood sugar control. However, even GLP-1 monotherapy has limitations in achieving weight loss in some patients. GIP (glucose-dependent insulinotropic polypeptide) is another natural hormone that plays important roles in glucose regulation and energy metabolism. Research has shown that combining GIP and GLP-1 signalling produces synergistic metabolic effects – better blood sugar control and greater weight loss than either agent alone. The challenge has been creating a single therapeutic that can effectively activate both GIP and GLP-1 receptors simultaneously.

What This Invention Does

Eli Lilly has engineered a novel peptide that simultaneously activates both GIP and GLP-1 receptors. This dual-action therapeutic combines the individual benefits of GIP and GLP-1 signalling into a single molecule, enabling coordinated activation of both metabolic pathways. The peptide design allows optimal engagement of both receptor targets while maintaining pharmaceutical stability and efficacy. The dual GIP/GLP-1 agonist addresses blood sugar regulation through multiple mechanisms: enhancing insulin secretion in response to glucose, slowing gastric emptying to moderate nutrient absorption, and reducing appetite through central nervous system signalling. Simultaneous activation of both receptors produces superior metabolic effects compared to selective GLP-1 agonists, with potential improvements in weight loss, blood sugar control, and metabolic parameters. The single-molecule approach offers practical advantages for patients – one therapeutic providing the benefits of dual pathway activation. In clinical studies of similar dual agonists, patients have achieved weight loss outcomes and metabolic improvements exceeding those with GLP-1 alone, representing a significant advancement in metabolic disease treatment.

Key Features

Dual Receptor Activation. Single peptide activates both GIP and GLP-1 receptors simultaneously for coordinated metabolic effects.

Enhanced Blood Sugar Control. Dual pathway activation provides superior glucose regulation compared to selective GLP-1 agonists.

Superior Weight Loss. Combined GIP/GLP-1 signalling produces greater weight reduction than GLP-1 monotherapy.

Metabolic Parameter Improvement. Addresses multiple aspects of metabolic dysfunction including insulin sensitivity and lipid profiles.

Single Therapeutic Administration. One molecule providing dual pathway benefits simplifies patient dosing and administration.

Who Is Behind It?

ELI LILLY AND COMPANY is developing this innovation with inventors Brian David Benneyworth and Elisa Razzoli. The company is based in United States. This patent application is a divisional of an earlier filing, indicating ongoing development and refinement of the core technology over multiple patent generations.

Why It Matters

The GLP-1 receptor agonist market has grown to exceed USD 25 billion annually, with dual GIP/GLP-1 agonists – such as tirzepatide – representing the next major therapeutic evolution. Superior metabolic outcomes compared to GLP-1 monotherapy position dual agonists to capture a substantial market share. The massive prevalence of type 2 diabetes and obesity ensures sustained demand for this therapeutic class.

Patent classifications focus on metabolic therapies (A61P 3/10, A61P 3/04), nephrological applications (A61P 13/12), and therapeutic peptides (A61K 38/26, A61K 45/06). This positioning emphasizes the pharmaceutical innovation within the endocrinology and metabolism field.

---

AU 2026201376 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates insulin release, suppresses glucagon, slows gastric emptying and reduces appetite. GLP-1 receptor agonists mimic these effects pharmacologically and have become foundational treatments for both type 2 diabetes and obesity.

GIP acts synergistically with GLP-1 to regulate energy metabolism and fat storage. Adding GIP receptor activation to GLP-1 agonism – as demonstrated by tirzepatide – produces greater weight loss and glycaemic improvements than GLP-1 monotherapy alone, validating the dual-agonist approach.